| 1 |
33685866 |
10.1158/1078-0432.CCR-21-0032 |
2022 |
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. |
MAP2K1 |
| 2 |
33759673 |
10.1080/17474086.2021.1908121 |
2022 |
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021? |
MAP2K1 |
| 3 |
33939500 |
10.1177/10668969211013402 |
2022 |
A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor. |
MAP2K1 |
| 4 |
34058070 |
10.1002/1878-0261.13033 |
2022 |
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. |
MAP2K1 |
| 5 |
35205796 |
10.3390/cancers14041050 |
2022 |
Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders. |
MAP2K1 |
| 6 |
35454811 |
10.3390/cancers14081904 |
2022 |
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients. |
MAP2K1 |
| 7 |
35609565 |
10.1182/bloodadvances.2022007322 |
2022 |
A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. |
MAP2K1 |
| 8 |
35834399 |
10.1097/PAS.0000000000001932 |
2022 |
Pediatric-Type Indolent B-Cell Lymphomas With Overlapping Clinical, Pathologic, and Genetic Features. |
MAP2K1 |
| 9 |
36038429 |
10.1016/j.annpat.2022.03.002 |
2022 |
[Rosai-Dorfman-Destombes disease with a misleading laryngeal presentation]. |
MAP2K1 |
| 10 |
31439678 |
10.3324/haematol.2019.230375 |
2021 |
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. |
MAP2K1 |
| 11 |
31868792 |
10.1097/IOP.0000000000001556 |
2021 |
Conjunctival Pediatric-Type Follicular Lymphoma. |
MAP2K1 |
| 12 |
31903146 |
10.7150/thno.39018 |
2021 |
Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma. |
MAP2K1 |
| 13 |
32929178 |
10.1038/s41379-020-00673-x |
2021 |
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. |
MAP2K1 |
| 14 |
33045225 |
10.1016/j.humpath.2020.09.014 |
2021 |
The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. |
MAP2K1 |
| 15 |
33211828 |
10.1182/bloodadvances.2020002944 |
2021 |
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. |
MAP2K1 |
| 16 |
33628588 |
10.20892/j.issn.2095-3941.2020.0098 |
2021 |
Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. |
MAP2K1 |
| 17 |
33676171 |
10.1016/j.anndiagpath.2021.151720 |
2021 |
From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature. |
MAP2K1 |
| 18 |
33971490 |
10.1016/j.bmc.2021.116186 |
2021 |
Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors. |
MAP2K1 |
| 19 |
30648436 |
10.1080/10428194.2018.1542148 |
2020 |
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. |
MAP2K1 |
| 20 |
30819919 |
10.3324/haematol.2018.211631 |
2020 |
A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma. |
MAP2K1 |
| 21 |
31056348 |
10.1016/j.clml.2019.03.015 |
2020 |
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. |
MAP2K1 |
| 22 |
28194436 |
10.1172/jci.insight.89473 |
2019 |
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. |
MAP2K1 |
| 23 |
28918710 |
10.1080/10428194.2017.1365853 |
2019 |
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. |
MAP2K1 |
| 24 |
29636358 |
10.1158/1078-0432.CCR-17-2452 |
2019 |
Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer. |
MAP2K1 |
| 25 |
29989027 |
10.18632/oncotarget.25601 |
2019 |
New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. |
MAP2K1 |
| 26 |
27034005 |
10.18632/oncotarget.8427 |
2018 |
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. |
MAP2K1 |
| 27 |
27241017 |
10.1080/10428194.2016.1185786 |
2018 |
Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. |
MAP2K1 |
| 28 |
28084334 |
10.1038/modpathol.2016.235 |
2018 |
Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. |
MAP2K1 |
| 29 |
28088512 |
10.1016/j.jtho.2017.01.004 |
2018 |
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. |
MAP2K1 |
| 30 |
29043551 |
10.1007/s12185-017-2359-1 |
2018 |
MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia. |
MAP2K1 |
| 31 |
30365139 |
10.3892/or.2018.6821 |
2018 |
miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway. |
MAP2K1 |
| 32 |
26757737 |
10.1007/s00401-016-1536-2 |
2017 |
Genomic characterization of primary central nervous system lymphoma. |
MAP2K1 |
| 33 |
26797410 |
10.1136/jclinpath-2015-203403 |
2017 |
Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. |
MAP2K1 |
| 34 |
27325104 |
10.1182/blood-2015-12-682591 |
2017 |
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. |
MAP2K1 |
| 35 |
27588400 |
10.18632/oncotarget.11730 |
2017 |
MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. |
MAP2K1 |
| 36 |
27878292 |
10.3892/or.2016.5262 |
2017 |
BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death. |
MAP2K1 |
| 37 |
28533310 |
10.1182/blood-2017-03-776278 |
2017 |
Mutations of <i>MAP2K1</i> are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. |
MAP2K1 |
| 38 |
28694326 |
10.1182/blood-2017-02-768234 |
2017 |
Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). |
MAP2K1 |
| 39 |
28892161 |
10.1002/path.4982 |
2017 |
A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors. |
MAP2K1 |
| 40 |
25729732 |
10.3343/alm.2015.35.2.257 |
2016 |
BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. |
MAP2K1 |
| 41 |
25804768 |
10.3109/10428194.2015.1032963 |
2016 |
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. |
MAP2K1 |
| 42 |
25858127 |
10.1684/abc.2015.1037 |
2016 |
[Chronic B-cell lymphoproliferative disorders with hairy cells]. |
MAP2K1 |
| 43 |
26426381 |
10.1097/PAS.0000000000000523 |
2016 |
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. |
MAP2K1 |
| 44 |
26566875 |
10.1158/2159-8290.CD-15-0913 |
2016 |
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. |
MAP2K1 |
| 45 |
26695526 |
10.1002/cncr.29812 |
2016 |
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. |
MAP2K1 |
| 46 |
26727971 |
10.1002/pbc.25854 |
2016 |
Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation. |
MAP2K1 |
| 47 |
26847289 |
10.3349/ymj.2016.57.2.373 |
2016 |
Anti-Proliferative Effects of Rutin on OLETF Rat Vascular Smooth Muscle Cells Stimulated by Glucose Variability. |
MAP2K1 |
| 48 |
26855057 |
10.1016/j.ejmg.2016.01.003 |
2016 |
Acute lymphoblastic leukemia in the context of RASopathies. |
MAP2K1 |
| 49 |
25184262 |
|
2015 |
New targets and new mechanisms in lung cancer. |
MAP2K1 |
| 50 |
25273224 |
10.1002/cncr.29042 |
2015 |
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. |
MAP2K1 |
| 51 |
25313141 |
10.18632/oncotarget.2533 |
2015 |
Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. |
MAP2K1 |
| 52 |
25394791 |
10.1126/science.1254721 |
2015 |
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. |
MAP2K1 |
| 53 |
25465126 |
10.1016/j.leukres.2014.10.009 |
2015 |
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells. |
MAP2K1 |
| 54 |
23208494 |
10.1038/onc.2012.544 |
2014 |
MEK1-RSK2 contributes to Hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination. |
MAP2K1 |
| 55 |
23665105 |
10.1016/j.ygcen.2013.04.033 |
2014 |
Transcriptomic profiling of progesterone in the male fathead minnow (Pimephales promelas) testis. |
MAP2K1 |
| 56 |
24375836 |
10.1002/cbin.10225 |
2014 |
MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim. |
MAP2K1 |
| 57 |
24711453 |
10.1074/jbc.M113.536490 |
2014 |
Triggering receptor expressed on myeloid cells 1 (TREM-1)-mediated Bcl-2 induction prolongs macrophage survival. |
MAP2K1 |
| 58 |
23234544 |
10.1042/BJ20121212 |
2013 |
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. |
MAP2K1 |
| 59 |
22242821 |
10.3109/10428194.2012.656102 |
2012 |
Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. |
MAP2K1 |
| 60 |
20523244 |
10.1097/MPH.0b013e3181df5e5b |
2011 |
Non-hodgkin lymphoma in a patient with cardiofaciocutaneous syndrome. |
MAP2K1 |
| 61 |
21131601 |
10.1158/1541-7786.MCR-10-0216 |
2011 |
Distinctive mechanism for sustained TGF-β signaling and growth inhibition: MEK1 activation-dependent stabilization of type II TGF-β receptors. |
MAP2K1 |
| 62 |
21277552 |
10.1016/S1470-2045(10)70087-5 |
2011 |
New driver mutations in non-small-cell lung cancer. |
MAP2K1 |
| 63 |
20526349 |
10.1038/nm.2166 |
2010 |
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. |
MAP2K1 |
| 64 |
19800577 |
10.1016/j.ccr.2009.08.015 |
2009 |
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. |
MAP2K1 |
| 65 |
17643425 |
10.1016/j.yexcr.2007.05.028 |
2007 |
Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells. |
MAP2K1 |
| 66 |
15655368 |
|
2006 |
Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation. |
MAP2K1 |
| 67 |
16189274 |
10.1182/blood-2005-05-1929 |
2006 |
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. |
MAP2K1 |
| 68 |
15090600 |
10.1242/jcs.00955 |
2005 |
Leukocyte-specific protein 1 targets the ERK/MAP kinase scaffold protein KSR and MEK1 and ERK2 to the actin cytoskeleton. |
MAP2K1 |
| 69 |
12645948 |
10.1002/immu.200310025 |
2003 |
CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. |
MAP2K1 |
| 70 |
12689928 |
10.1182/blood-2002-11-3507 |
2003 |
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. |
MAP2K1 |
| 71 |
12220533 |
10.1016/s0003-9861(02)00369-7 |
2002 |
CD40-mediated tumor necrosis factor receptor-associated factor 3 signaling upregulates IL-4-induced germline Cepsilon transcription in a human B cell line. |
MAP2K1 |
| 72 |
10997882 |
10.1034/j.1600-0609.2000.90112.x |
2000 |
Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42/44 (MAPK), ELK-1 transcription factor and serine/threonine kinase AKT. |
MAP2K1 |
| 73 |
10233955 |
10.1128/JVI.73.6.4931-4940.1999 |
1999 |
Feline leukemia virus long terminal repeat activates collagenase IV gene expression through AP-1. |
MAP2K1 |
| 74 |
9498749 |
|
1998 |
Differential coupling of membrane Ig and CD40 to the extracellularly regulated kinase signaling pathway. |
MAP2K1 |
| 75 |
9751120 |
|
1998 |
Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. |
MAP2K1 |
| 76 |
9840924 |
10.1038/sj.onc.1202460 |
1998 |
Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB. |
MAP2K1 |
| 77 |
9278316 |
|
1997 |
Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK2. |
MAP2K1 |
| 78 |
8649450 |
10.1016/0161-5890(95)00134-4 |
1996 |
Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities. |
MAP2K1 |
| 79 |
8816388 |
|
1996 |
Activation of the Ras signaling pathway by the CD40 receptor. |
MAP2K1 |
| 80 |
8871635 |
|
1996 |
Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. |
MAP2K1 |
| 81 |
7717978 |
10.1042/bj3070215 |
1995 |
The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line. |
MAP2K1 |
Datasets
Models
